Movement Disorders (revue) - Exploration (Accueil)

Index « Keywords » - entrée « Clinical Trials as Topic »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Clinical Protocols (standards) < Clinical Trials as Topic < Clinical Trials as Topic (economics)  Facettes :

List of bibliographic references indexed by Clinical Trials as Topic

Number of relevant bibliographic references: 53.
[20-40] [0 - 20][0 - 50][40-52][40-60]
Ident.Authors (with country if any)Title
002480 (2009) Bernard Ravina [États-Unis] ; Caroline Tanner [États-Unis] ; Diane Dieuliis [États-Unis] ; Shirley Eberly [États-Unis] ; Emily Flagg [États-Unis] ; Wendy R. Galpern [États-Unis] ; Stanley Fahn [États-Unis] ; Christopher G. Goetz [États-Unis] ; Stephen Grate [États-Unis] ; Roger Kurlan [États-Unis] ; Anthony E. Lang [Canada] ; Kenneth Marek [États-Unis] ; Karl Kieburtz [États-Unis] ; David Oakes [États-Unis] ; Robin Elliott [États-Unis] ; Ira Shoulson [États-Unis]A longitudinal program for biomarker development in Parkinson's disease: A feasibility study
002556 (2008) Claudia Trenkwalder [Allemagne] ; Wayne A. Hening [États-Unis] ; Pasquale Montagna [Italie] ; Wolfgang H. Oertel [Allemagne] ; Richard P. Allen [États-Unis] ; Arthur S. Walters [États-Unis] ; Joao Costa [Portugal] ; Karin Stiasny-Kolster [Allemagne] ; Cristina Sampaio [Portugal]Treatment of restless legs syndrome: An evidence‐based review and implications for clinical practice
002593 (2008) Anthony H. V. Schapira [Royaume-Uni]The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
002995 (2008) Carl E. Clarke [Royaume-Uni]Are delayed‐start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
002B20 (2007) Claudia Trenkwalder [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Richard Allen [États-Unis] ; Diego Garcia-Borreguero [Espagne]Tireless work on restless legs: Guest editors' introduction
002C67 (2007) Susanne May [États-Unis] ; Sid Gilman [États-Unis] ; B. Brooke Sowell [États-Unis] ; Ronald G. Thomas [États-Unis] ; Matthew B. Stern [États-Unis] ; Amy Colcher [États-Unis] ; Caroline M. Tanner [États-Unis] ; Neng Huang [États-Unis] ; Peter Novak [États-Unis] ; Stephen G. Reich [États-Unis] ; Joseph Jankovic [États-Unis] ; William G. Ondo [États-Unis] ; Phillip A. Low [États-Unis] ; Paola Sandroni [États-Unis] ; Axel Lipp [États-Unis] ; Frederick J. Marshall [États-Unis] ; Frederick Wooten [États-Unis] ; Clifford W. Shults [États-Unis]Potential outcome measures and trial design issues for multiple system atrophy
002E72 (2007) Pablo Martinez-Martin [Espagne] ; Günther Deuschl [Allemagne]Effect of medical and surgical interventions on health‐related quality of life in Parkinson's disease
003010 (2007) Ralf Kohnen [Allemagne] ; Richard P. Allen [États-Unis] ; Heike Benes [Allemagne] ; Diego Garcia-Borreguero [Espagne] ; Wayne A. Hening [États-Unis] ; Karin Stiasny-Kolster [Allemagne] ; Marco Zucconi [Italie]Assessment of restless legs syndrome—Methodological approaches for use in practice and clinical trials
003504 (2006) Todd B. Sherer [États-Unis] ; Brian K. Fiske [États-Unis] ; Clive N. Svendsen [États-Unis] ; Anthony E. Lang [Canada] ; J. William Langston [États-Unis]Crossroads in GDNF therapy for Parkinson's disease
003E92 (2003) Takashi Nomura [Japon] ; Yuichi Inoue [Japon] ; Hidetaka Mitani [Japon] ; Ryuzo Kawahara [Japon] ; Masahiro Miyake [Japon] ; Kenji Nakashima [Japon]Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease
003F75 (2003) P. K. Morrish [Royaume-Uni]REAL and CALM: What have we learned?
003F81 (2003) Werner Poewe [Autriche]Psychosis in Parkinson's disease
004032 (2003) Gregor K. Wenning [Autriche] ; Felix Geser [Autriche] ; Michaela Stampfer-Kountchev [Autriche] ; François Tison [Autriche]Multiple system atrophy: An update
004047 (2003) Markus Naumann [Allemagne] ; A. Peter Moore [Royaume-Uni]Long‐term safety of botulinum toxin type A
004070 (2003) Paul K. Morrish [Royaume-Uni]How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?
004140 (2003) David J. Burn [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni]Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease
004415 (2002) Paul Morrish [Royaume-Uni]Is it time to abandon functional imaging in the study of neuroprotection?
004460 (2002) Anne-Catherine Bachoud-Lévi [France] ; Philippe Hantraye [France] ; Marc Peschanski [France]Fetal neural grafts for Huntington's disease: A prospective view
004816 (2001) Joseph H. FriedmanEffects of reviewing DATATOP videotapes on IQ and MMPI in PSG coordinators and investigators, or, whatever happened to Tony Lang?
004943 (2000) Stewart A. Factor [États-Unis]The initial treatment of Parkinson's disease
004A99 (2000) Andrew D. Siderowf [États-Unis] ; Robert G. Holloway [États-Unis] ; Matthew B. Stern [États-Unis]Cost‐effectiveness analysis in Parkinson's disease: Determining the value of interventions

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Clinical Trials as Topic" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Clinical Trials as Topic" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Clinical Trials as Topic
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024